在患有固体瘤和功能障碍的患者中,德诺苏马布诱导的低热血症:多中心,回顾性,观察性研究
Kazuyo Nakamura1, Michihiro Kaya2, Yuki Yanagisawa3
1Shizuoka General Hospital, -27-1, Kita-ando, Aoi-ku, 420-8527, Shizuoka, Japan. kazuyo-nakamura@i.shizuoka-pho.jp.
BMC cancer
|February 15, 2024
概括
针对骨转移的登索苏马布治疗可能会导致低血症,特别是在严重功能障碍的患者中. 仔细监测血清水平对于接受denosumab的功能受损患者至关重要.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨转移在晚期癌症中很常见,需要使用骨修饰剂.
- 在严重功能障碍患者中禁用佐莱德龙酸,但在这种人群中,德诺苏马布的安全性需要进一步调查.
- 了解德诺苏马布对患有功能变化的患者水平的影响,对于安全治疗至关重要.
研究的目的:
- 为了研究功能和在denosumab治疗期间低血症的发展之间的关联.
- 在接受denosumab的癌症患者中确定低血症的危险因素.
- 为了告知临床实践关于在患有功能障碍的患者中使用denosumab.
主要方法:
- 分析了一组524名患有骨转移的癌症患者,他们接受了denosumab治疗.
- 患者根据肌素清除率 (Ccr) 分为四组:正常,轻度,中度和严重的功能障碍.
- 低血症的发病率和危险因素被评估使用阿尔伯明调整的水平和统计分析.
主要成果:
- 严重功能障碍患者 (62.5%) 的低血症 (≥1级) 发生率明显高于正常功能患者 (32.0%).
- 针对白蛋白调整的血清水平对于准确的低血症评估是必要的.
- 在治疗前,低血清和严重的功能障碍被确定为低血症的重要危险因素.
结论:
- 在患有严重功能障碍的患者中,denosumab诱导的低血症更为频繁.
- 专蛋白调整对于评估在denosumab患者的低血症至关重要.
- 建议在接受denosumab的患者中密切监测水平和功能.
相关概念视频
Skeleton and Calcium Homeostasis
4.5K
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
4.5K
Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Hormones and Bone Tissue
2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K
Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
Synthesis and Functions of Calcitonin
1.8K
Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
1.8K
Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89


